Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Financial press releases

08 September 2016

GenSight Biologics receives approval to include teenage patients in RESCUE and REVERSE Phase III trials with GS010 in Leber’s Hereditary Optic Neuropathy

01 September 2016

GenSight Biologics receives Orphan Drug Designation and Advanced Therapy Medicinal Product classification in Europe for GS030 in Retinitis Pigmentosa

11 August 2016

GenSight Biologics confirms the success of its IPO by exercising 88.9% of the over-allotment option

11 August 2016

GenSight Biologics announces the implementation of a liquidity contract with Oddo & Cie

13 July 2016

GenSight Biologics announces successful IPO on Euronext Paris

05 July 2016

GenSight Biologics launches its Initial Public Offering on the regulated market of Euronext in Paris

08 June 2016

GenSight Biologics announces additional promising results of its Phase I/II study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)

24 May 2016

GenSight Biologics announces the registration of its document de base in relation to its planned IPO on Euronext’s regulated market in Paris

29 February 2016

GenSight Biologics Enrolls First Patient in Pivotal Phase III Program of GS010 in Leber’s Hereditary Optic Neuropathy

10 September 2015

GenSight Biologics Receives IND Acceptance from FDA to Enter Phase III with GS010

  • View previous 9 articles
  • 1
  • …
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • View next 9 articles
© 2025 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page